Author

C. J. Der

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Approach:experimental assay· 5 Research Focus:cancer & tumor microenvironment· 4 Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. D. Cox· 2 shared B. Papke· 2 shared K. Drizyte-Miller· 2 shared L. M. Graves· 2 shared M. Pierobon· 2 shared P. S. Hibshman· 2 shared A. A. Amparo· 1 shared A. A. Iwanowicz· 1 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. D. Cox

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma

U. N. Wasko, J. Jiang, A. C. Garcia, Y. Wang, B. Lee, M. Orlen, K. Drizyte-Miller, M. Menard, J. Dilly, S. A. Sastra, C. F. Palermo, T. Dalton, M. C. Hasselluhn, A. R. Decker-Farrell, S. Chang, , R. H Vonderheide

This study evaluates the therapeutic potential of RMC-7977, a broad-spectrum RAS inhibitor, in pancreatic ductal adenocarcinoma models, showing strong anti-tumor effects with minimal impact on normal tissues.

bioRxiv · Dec 3, 2023 · PreprintCancer Biology

Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant Cancers

D. P. Nussbaum, C. A. Martz, A. M. Waters, A. Barrera, J. C. Rutter, C. G. Cerda-Smith, A. E. Stewart, C. Wu, M. Cakir, C. B. Levandowski, D. E. Kantrowitz, S. J. McCall, M. Pierobon, E. Petricoin, J. J. Smith, , K. C. Wood

This study shows that Mediator kinase inhibition prevents resistance to ERK/MAPK inhibitors in KRAS-mutant cancers by blocking transcriptional plasticity.

bioRxiv · Sep 17, 2022 · PreprintCancer Biology

Characterization of TR-107, a Novel Chemical Activator of the Human Mitochondrial Protease ClpP

E. M. J. Fennell, L. J. Aponte-Collazo, J. D. Wynn, K. Drizyte-Miller, E. Leung, Y. E. Greer, P. R. Graves, A. A. Iwanowicz, H. Ashamalla, E. Holmuhamedov, H. Lang, D. S. Karanewsky, C. J. Der, W. A. Houry, S. Lipkowitz, , L. M. Graves

This paper characterizes TR-107, a novel ClpP activator, showing potent antitumor effects against triple-negative breast cancer through mitochondrial metabolic disruption.

bioRxiv · Feb 14, 2022Pharmacology & Toxicology

Defining the KRAS-regulated kinome in KRAS-mutant pancreatic cancer

J. N. Diehl, J. E. Klomp, K. R. Snare, D. R. Blake, P. S. Hibshman, Z. D. Kaiser, T. S. K. Gilbert, E. Baldelli, M. Pierobon, B. Papke, R. Yang, R. G. Hodge, N. U. Rashid, E. F. Petricoin, L. E. Herring, , C. J. Der

This study identifies upregulated and downregulated kinases in KRAS-mutant pancreatic cancer using chemical proteomics, revealing potential therapeutic targets.

bioRxiv · Apr 27, 2021 · PreprintCancer Biology

Silencing of oncogenic KRAS by mutant-selective small interfering RNA

B. Papke, S. H. Azam, A. Y. Feng, A. E. D. Van Swearingen, C. Gutierrez-Ford, P. S. Pallan, M. Egli, A. D. Cox, C. J. Der, C. V. Pecot

This study develops a mutant-selective siRNA, EFTX-D1, that targets KRAS mutations in codons 12 and 13, reducing mutant KRAS expression and impairing cancer cell proliferation.

bioRxiv · Oct 8, 2020Cancer Biology

Facile real time detection of membrane colocalization of RAS superfamily GTPase proteins in living cells

Y.-C. Li, L. Wang, T. K. Hayes, M. N. Sutton, R. C. Bast, F. McCormick, C. J. Der, G. M. Wahl

This study uses ReBiL2.0 to show that the C-terminal HVR-CAAX domain directs KRAS to colocalize with other prenylated proteins, impacting its signaling.

bioRxiv · Jul 15, 2018Cancer Biology